Asunto(s)
Ascitis/terapia , Líquido Ascítico , Fallo Renal Crónico/terapia , Trasplante de Riñón , Cirrosis Hepática/terapia , Trasplante de Hígado , Diálisis Renal/métodos , Listas de Espera , Adulto , Ascitis/diagnóstico , Ascitis/etiología , Humanos , Fallo Renal Crónico/complicaciones , Fallo Renal Crónico/diagnóstico , Cirrosis Hepática/complicaciones , Cirrosis Hepática/diagnóstico , Masculino , Resultado del TratamientoRESUMEN
BACKGROUND/AIMS: The optimal serum bicarbonate level is controversial for patients who are undergoing hemodialysis (HD). In this study, we analyzed the impact of serum bicarbonate levels on mortality among HD patients. METHODS: Prevalent HD patients were selected from the Clinical Research Center registry for End Stage Renal Disease cohort in Korea. Patients were categorized into quartiles according to their total carbon dioxide (tCO2) levels: quartile 1, a tCO2 of < 19.4 mEq/L; quartile 2, a tCO2 of 19.4 to 21.5 mEq/L; quartile 3, a tCO2 of 21.6 to 23.9 mEq/L; and quartile 4, a tCO2 of ≥ 24 mEq/L. Cox regression analysis was used to calculate the adjusted hazard ratio (HR) and confidence interval (CI) for mortality. RESULTS: We included 1,159 prevalent HD patients, with a median follow-up period of 37 months. Kaplan-Meier analysis revealed that the all-cause mortality was significantly higher in patients from quartile 4, compared to those from the other quartiles (p = 0.009, log-rank test). The multivariate Cox proportional hazard model revealed that patients from quartile 4 had significantly higher risk of mortality than those from quartile 1, 2 and 3, after adjusting for the clinical variables in model 1 (HR, 1.99; 95% CI, 1.15 to 3.45; p = 0.01) and model 2 (HR, 1.82; 95% CI, 1.03 to 3.22; p = 0.04). CONCLUSIONS: Our data indicate that high serum bicarbonate levels (a tCO2 of ≥ 24 mEq/L) were associated with increased mortality among prevalent HD patients. Further effort might be necessary in finding the cause and correcting metabolic alkalosis in the chronic HD patients with high serum bicarbonate levels.
Asunto(s)
Bicarbonatos/sangre , Fallo Renal Crónico/terapia , Diálisis Renal/mortalidad , Adulto , Anciano , Biomarcadores/sangre , Distribución de Chi-Cuadrado , Femenino , Humanos , Estimación de Kaplan-Meier , Fallo Renal Crónico/sangre , Fallo Renal Crónico/diagnóstico , Fallo Renal Crónico/mortalidad , Masculino , Persona de Mediana Edad , Análisis Multivariante , Prevalencia , Modelos de Riesgos Proporcionales , Estudios Prospectivos , Sistema de Registros , Diálisis Renal/efectos adversos , República de Corea/epidemiología , Factores de Riesgo , Resultado del Tratamiento , Regulación hacia ArribaRESUMEN
BACKGROUND/AIMS: Inadequacy of dialysis is associated with morbidity and mortality in chronic hemodialysis (HD) patients. Blood flow rate (BFR) during HD is one of the important determinants of increasing dialysis dose. However, the optimal BFR is unclear. In this study, we investigated the impact of the BFR on all-cause mortality in chronic HD patients. METHODS: Prevalent HD patients were selected from Clinical Research Center registry for end-stage renal disease cohort in Korea. We categorized patients into two groups by BFR < 250 and ≥ 250 mL/min according to the median value of BFR 250 mL/min in this study. The primary outcome was all-cause mortality. RESULTS: A total of 1,129 prevalent HD patients were included. The number of patients in the BFR < 250 mL/min was 271 (24%) and in the BFR ≥ 250 mL/min was 858 (76%). The median follow-up period was 30 months. Kaplan-Meier analysis showed that the mortality rate was significantly higher in patients with BFR < 250 mL/min than those with BFR ≥ 250 mL/min (p = 0.042, log-rank). In the multivariate Cox regression analyses, patients with BFR < 250 mL/min had higher all-cause mortality than those with BFR ≥ 250 mL/min (hazard ratio, 1.66; 95% confidence interval, 1.00 to 2.73; p = 0.048). CONCLUSIONS: Our data showed that BFR < 250 mL/min during HD was associated with higher all-cause mortality in chronic HD patients.
Asunto(s)
Fallo Renal Crónico/mortalidad , Fallo Renal Crónico/terapia , Diálisis Renal/mortalidad , Adulto , Anciano , Velocidad del Flujo Sanguíneo , Causas de Muerte , Distribución de Chi-Cuadrado , Femenino , Humanos , Estimación de Kaplan-Meier , Fallo Renal Crónico/diagnóstico , Fallo Renal Crónico/fisiopatología , Masculino , Persona de Mediana Edad , Análisis Multivariante , Prevalencia , Modelos de Riesgos Proporcionales , Estudios Prospectivos , Sistema de Registros , Diálisis Renal/efectos adversos , Diálisis Renal/métodos , República de Corea/epidemiología , Factores de Riesgo , Factores de Tiempo , Resultado del TratamientoAsunto(s)
Absceso/microbiología , Diabetes Mellitus , Pielonefritis/microbiología , Quiste del Uraco/microbiología , Uraco/anomalías , Absceso/diagnóstico por imagen , Absceso/terapia , Enfermedad Aguda , Antibacterianos/uso terapéutico , Biopsia , Cistoscopía , Diabetes Mellitus/sangre , Diabetes Mellitus/diagnóstico , Diabetes Mellitus/tratamiento farmacológico , Errores Diagnósticos , Drenaje , Femenino , Humanos , Persona de Mediana Edad , Valor Predictivo de las Pruebas , Pielonefritis/diagnóstico , Pielonefritis/terapia , Tomografía Computarizada por Rayos X , Resultado del Tratamiento , Ultrasonografía , Quiste del Uraco/diagnóstico por imagen , Quiste del Uraco/terapia , Uraco/diagnóstico por imagen , Infecciones Urinarias/diagnósticoRESUMEN
Invasive aspergillosis (IA), generally considered an opportunistic infection in immunocompromised hosts, is associated with high morbidity and mortality. IA commonly occurs in the respiratory tract with isolated reports of aspergillosis infection in the nasal sinuses, central nervous system, skin, liver, and urinary tract. Extra-pulmonary aspergillosis is usually observed in disseminated disease. To date, there are a few studies regarding primary and disseminated gastrointestinal (GI) aspergillosis in immunocompromised hosts. Only a few cases of primary GI aspergillosis in non-immunocompromised hosts have been reported; of these, almost all of them involved the upper GI tract. We describe a very rare case of IA involving the lower GI tract in the patient without classical risk factors that presented as multiple colon perforations and was successfully treated by surgery and antifungal treatment. We also review related literature and discuss the characteristics and risk factors of IA in the immunocompetent hosts without classical risk factors. This case that shows IA should be considered in critically ill patients, and that primary lower GI aspergillosis may also occur in the immunocompetent hosts without classical risk factors.
Asunto(s)
Antifúngicos/uso terapéutico , Aspergilosis/diagnóstico , Aspergillus/aislamiento & purificación , Colon/cirugía , Inmunocompetencia , Anfotericina B/administración & dosificación , Anfotericina B/uso terapéutico , Antifúngicos/administración & dosificación , Aspergilosis/tratamiento farmacológico , Aspergilosis/microbiología , Aspergilosis/cirugía , Colon/diagnóstico por imagen , Colon/microbiología , Enfermedades del Colon/diagnóstico , Enfermedades del Colon/terapia , Terapia Combinada , Humanos , Laparotomía , Masculino , Persona de Mediana Edad , Radiografía , Resultado del Tratamiento , Voriconazol/administración & dosificación , Voriconazol/uso terapéuticoAsunto(s)
Glomerulonefritis/inmunología , Inmunoglobulina M/análisis , Riñón/inmunología , Síndrome Nefrótico/inmunología , Neurofibromatosis 1/complicaciones , Adulto , Inhibidores de la Enzima Convertidora de Angiotensina/uso terapéutico , Biomarcadores/análisis , Biopsia , Quimioterapia Combinada , Femenino , Técnica del Anticuerpo Fluorescente , Glomerulonefritis/diagnóstico , Glomerulonefritis/tratamiento farmacológico , Glucocorticoides/uso terapéutico , Humanos , Riñón/efectos de los fármacos , Riñón/patología , Síndrome Nefrótico/diagnóstico , Síndrome Nefrótico/tratamiento farmacológico , Neurofibromatosis 1/diagnóstico , Neurofibromatosis 1/inmunología , Valor Predictivo de las Pruebas , Factores de Riesgo , Resultado del TratamientoAsunto(s)
Neoplasias de la Corteza Suprarrenal/metabolismo , Adenoma Corticosuprarrenal/metabolismo , Aldosterona/biosíntesis , Hidrocortisona/biosíntesis , Neoplasias de la Corteza Suprarrenal/diagnóstico , Neoplasias de la Corteza Suprarrenal/cirugía , Adrenalectomía , Adenoma Corticosuprarrenal/diagnóstico , Adenoma Corticosuprarrenal/cirugía , Adulto , Síndrome de Cushing/diagnóstico , Femenino , Humanos , Hiperaldosteronismo/metabolismoRESUMEN
A 61-year-old man presented with lower extremity paralysis and severe hypokalemia. His thyroid function test showed thyrotoxicosis. Despite attempts to correct his hypokalemia, he developed pulseless polymorphic ventricular tachycardia two hours later. He was successfully resuscitated after defibrillation. We performed continuous venovenous hemodiafiltration for 10 days due to acute kidney injury and rhabdomyolysis. We observed life-threatening polymorphic ventricular tachycardia requiring urgent defibrillation, as well as rhabdomyolysis requiring dialysis during the transient thyrotoxic phase of painless thyroiditis. Pay attention to the possibility of the development of life-threatening ventricular tachycardia associated with hypokalemia in the setting of thyroiditis and thyrotoxic paralysis.
Asunto(s)
Hipopotasemia/etiología , Parálisis Periódica Hipopotasémica/etiología , Rabdomiólisis/etiología , Taquicardia Ventricular/etiología , Tirotoxicosis/etiología , Humanos , Hipopotasemia/terapia , Parálisis Periódica Hipopotasémica/terapia , Masculino , Persona de Mediana Edad , Rabdomiólisis/terapia , Taquicardia Ventricular/terapia , Tirotoxicosis/terapia , Resultado del Tratamiento , Fibrilación Ventricular/etiologíaRESUMEN
BACKGROUND: Osmotic demyelination syndrome (ODS) primarily occurs after rapid correction of severe hyponatremia. There are no proven effective therapies for ODS, but we describe the first case showing the successful treatment of central pontine myelinolysis (CPM) by plasma exchange, which occurred after rapid development of hypernatremia from intravenous sodium bicarbonate therapy. CASE PRESENTATION: A 40-year-old woman presented with general weakness, hypokalemia, and metabolic acidosis. The patient was treated with oral and intravenous potassium chloride, along with intravenous sodium bicarbonate. Although her bicarbonate deficit was 365 mEq, we treated her with an overdose of intravenous sodium bicarbonate, 480 mEq for 24 hours, due to the severity of her acidemia and her altered mental status. The next day, she developed hypernatremia with serum sodium levels rising from 142.8 mEq/L to 172.8 mEq/L. Six days after developing hypernatremia, she exhibited tetraparesis, drooling, difficulty swallowing, and dysarthria, and a brain MRI revealed high signal intensity in the central pons with sparing of the peripheral portion, suggesting CPM. We diagnosed her with CPM associated with the rapid development of hypernatremia after intravenous sodium bicarbonate therapy and treated her with plasma exchange. After two consecutive plasma exchange sessions, her neurologic symptoms were markedly improved except for mild diplopia. After the plasma exchange sessions, we examined the patient to determine the reason for her symptoms upon presentation to the hospital. She had normal anion gap metabolic acidosis, low blood bicarbonate levels, a urine pH of 6.5, and a calyceal stone in her left kidney. We performed a sodium bicarbonate loading test and diagnosed distal renal tubular acidosis (RTA). We also found that she had Sjögren's syndrome after a positive screen for anti-Lo, anti-Ra, and after the results of Schirmer's test and a lower lip biopsy. She was discharged and treated as an outpatient with oral sodium bicarbonate and potassium chloride. CONCLUSION: This case indicates that serum sodium concentrations should be carefully monitored in patients with distal RTA receiving intravenous sodium bicarbonate therapy. We should keep in mind that acute hypernatremia and CPM can be associated with intravenous sodium bicarbonate therapy, and that CPM due to acute hypernatremia may be effectively treated with plasma exchange.
Asunto(s)
Cromatos/administración & dosificación , Cromatos/efectos adversos , Hipernatremia/inducido químicamente , Hipernatremia/terapia , Mielinólisis Pontino Central/inducido químicamente , Mielinólisis Pontino Central/terapia , Intercambio Plasmático/métodos , Enfermedad Aguda , Adulto , Femenino , Humanos , Hipernatremia/diagnóstico , Hipopotasemia/complicaciones , Hipopotasemia/tratamiento farmacológico , Inyecciones Intravenosas , Mielinólisis Pontino Central/diagnóstico , Resultado del TratamientoRESUMEN
A 41-year-old woman who was diagnosed with myocarditis presented eosinophilia. Since the antibody against Toxocara canis (T. canis) was positive, we diagnosed that she had visceral larva migrans due to T. canis associated with myocarditis. She was treated with oral albendazole and prednisolone for two weeks, eosinophil count and hepatic enzymes were normalized after completion of treatment. This is the first report of myocarditis caused by T. canis infection in Korea.
RESUMEN
The Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome is a congenital disorder characterized by aplasia of the uterus and the upper part of the vagina in an XX individual with normal development of secondary sexual characteristics. Individuals with this syndrome may also present with renal and skeletal abnormalities. We report a case of a 16-year-old girl presenting with thyrotoxicosis and primary amenorrhea. After being diagnosed with Graves disease, this patient was placed on antithyroid medication. Although her thyroid function normalized, she did not start to menstruate. Therefore, we assessed her primary amenorrhea and diagnosed the patient with MRKH syndrome through pelvic imaging. To our knowledge, an association between Graves disease and MRKH syndrome has not yet been reported.